News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Linxon, Hitachi Energy, and FTC Solar signed an MoU to jointly deliver utility-scale solar and battery projects across North America to speed grid modernization.
  • Analysts pitch Uber as a long-term buy at about $69, citing $9.44B free cash flow and a ~14.5 PE while noting execution risks.
  • Redwire reports accelerating revenue, margin recovery, and a record backlog, making RDW a tactical speculative long.
  • OpenTable says Canadian dining rose 13% year-over-year, signaling stronger local consumer spending and restaurant demand.
  • H&R Block is hiring tax professionals and client-facing associates to expand capacity ahead of the 2026 tax season.
  • Chris-Craft, owned by Winnebago, launched the Corsair 27 to re-enter the luxury boating market with upgraded design and tech.

Latest Articles

Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier

Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier

Denali Therapeutics' CEO Dr. Ryan Watts will deliver the opening address at the 2026 Alzheimer's Association International Conference to showcase breakthroughs in their proprietary TransportVehicle™ platform, enabling biologic drugs to cross the blood-brain barrier. The company is advancing investigational therapies targeting tau and amyloid beta f…

20/20 BioLabs Highlights Investor Webinar Focused on OneTest™ for Medicare, Serial Biomarker Tracking, and Strong Q2 Revenue Growth

20/20 BioLabs Highlights Investor Webinar Focused on OneTest™ for Medicare, Serial Biomarker Tracking, and Strong Q2 Revenue Growth

20/20 BioLabs presented its strategy during an investor webinar to advance OneTest™ for Cancer as an affordable multi-cancer early detection blood test targeting Medicare reimbursement under new federal legislation starting 2028. The company emphasized its differentiating serial biomarker tracking technology, real-world evidence generation from hig…

MKS Named by Time as One of America’s Best Companies for 2026

MKS Named by Time as One of America’s Best Companies for 2026

MKS Inc., a global technology provider serving semiconductor manufacturing and specialty industrial applications, has been named one of America’s Best Companies for 2026 by Time and Statista. This marks the second consecutive year MKS received this recognition, which evaluates companies based on employee satisfaction, financial success, and sustain…

Tilray Medical Announces Commercial Launch of Medical Cannabis in Panama, Expanding Patient Access Across Latin America

Tilray Medical Announces Commercial Launch of Medical Cannabis in Panama, Expanding Patient Access Across Latin America

Tilray Medical, a division of Tilray Brands, announced the commercial launch of its medical cannabis product, Tilray Oral Solution CBD100, in Panama through partnership with local pharmacy chain Farmacias Arrocha. This launch marks a key step in Tilray's global expansion and advances patient access to regulated, pharmaceutical-quality cannabinoid m…

KPMG UK to Reduce Central Support Staff by 10% as Integration Progresses

KPMG UK to Reduce Central Support Staff by 10% as Integration Progresses

KPMG's UK business has proposed a 10% reduction across its central support teams as part of integration activity following a 2024 merger with its Switzerland operations. The move, which could affect roughly 200 roles, is subject to consultation under UK employment law. The firm says the proposals aim to remove duplication, leverage technology inves…

Buy the Dip: AstraZeneca Sell-Off After Trial Setback Looks Overdone

Buy the Dip: AstraZeneca Sell-Off After Trial Setback Looks Overdone

AstraZeneca plunged more than 10% intraday after headlines tied the stock to a heart-disease trial setback. That knee-jerk move created a tradable opportunity: the company’s scale, pipeline depth, and cash flow profile cushion the hit. This trade plan targets a mean-reversion bounce over the next 45 trading days while keeping a tight stop to respec…

Camtek: Premium Multiples But Real Growth - Buy the Conditional Runway

Camtek: Premium Multiples But Real Growth - Buy the Conditional Runway

Camtek (CAMT) has premium multiples for a reason: a sticky niche in advanced packaging and HBM inspection, a recent beat-and-raise quarter and a still-large addressable-market runway. Valuation is rich, momentum is choppy and short interest keeps the stock volatile. Recommended action: buy on a tactical pullback with strict risk controls and a 180-…

Warsh Names High-Profile Task Forces to Reexamine Fed Policy Operations

Warsh Names High-Profile Task Forces to Reexamine Fed Policy Operations

Federal Reserve Chairman Kevin Warsh has appointed leaders for five independent task forces to conduct a top-to-bottom review of the central bank's monetary policy operations. While reaffirming the Fed's dual mandate - price stability and maximum employment - Warsh said the economy's rapid evolution requires updated tools, data and communication st…

Warsh Assembles Wide-Ranging External Panels to Reassess Fed Operations

Warsh Assembles Wide-Ranging External Panels to Reassess Fed Operations

Federal Reserve Chair Kevin Warsh has appointed a diverse set of economists, former central bankers and private-sector figures to lead five independent task forces that will review the Fed's operations. The groups, announced after Warsh's first policy meeting on June 16-17 and formally named on Thursday, will examine technical matters including bal…

Goldman Tightens Rules, Bans Staff From Most Prediction-Market Bets

Goldman Tightens Rules, Bans Staff From Most Prediction-Market Bets

Goldman Sachs has revised its personal trading policy to prohibit employees from participating in most prediction-market trading. The rule excludes only sports and entertainment wagers and explicitly bans event contracts tied to specific companies, including Goldman Sachs itself, as well as bets on elections and financial market performance. Violat…

Palantir at a Premium: A Mid-Term Short on 140x Earnings

Palantir at a Premium: A Mid-Term Short on 140x Earnings

Palantir trades with a market value north of $300 billion while sporting a trailing P/E in the ~140-150x range and EV/FCF near 117x. That pricing assumes years of flawless execution and sustained hyper-growth. This trade idea outlines a mid-term short with entry at $129.00, a stop at $150.00, and a primary target of $100.00 over roughly 45 trading …